Leukemia

Many patients with cancer do not qualify for clinical trials because of comorbidities or other health problems. However, a recent study found that many of these patients can actually benefit from trials.

Several trials testing vadastuximab talirine for use in patients with AML were recently halted, according to the drug's manufacturer.

Recent studies found that for certain patients with CML, it is possible to safely reduce or stop TKI treatment.

CTL019, a CAR T-cell therapy, had a high response rate for young patients with relapsed/refractory ALL in a recent phase 2 study.

Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.

The treatment landscape for chronic lymphocytic leukemia (CLL) is going to drastically change over the next decade or so, says Jose Leis, M.D.

Through music, Christian Hoff shares his message of hope for patients and survivors of cancer.

Midostaurin was granted a priority review for a new drug application by the FDA to treat a subset of patients with acute myeloid leukemia.

The NCCN updated their guidelines on treatment for myeloproliferative neoplasms (MPNs), outlining diagnosis, treatment and care strategies.

Checkpoint inhibitors such as Opdivo and Yervoy are showing promise in treating MDS and AML.

By mitigating some of the financial burdens, The Leukemia & Lymphoma Society helps patients better stick to treatment regimens.

The Beat AML trial just launched, and researchers are hoping it will find better treatment for patients with acute myeloid leukemia.

Targeted drugs known as TKIs have improved the prognosis for patients with chronic myeloid leukemia.

Subsets of patients with acute lymphoblastic leukemia are getting more personalized care.

Patients with CML who are insured by Medicare are choosing to delay potentially life-saving treatment due to high costs.

Novel therapeutic agents have been developed for chronic lymphocytic leukemia (CLL), but their advantage over traditional treatments for this type of cancer have yet to be proved.

There are now more personalized treatment options for patients with CLL.

The FDA has approved Blincyto (blinatumomab) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL.

Pracinostat was granted a breakthrough therapy designation by the FDA for use in some patients with AML.

Researchers are hoping to harness the leukemia-killing antibodies made by cured AML patients to treat others with the disease.

As new therapies get approved and continue to be investigated, treatment for CLL is rapidly evolving.

A CAR-T Cell therapy trial was put on hold by the FDA after the death of three participants.

A recent study identified the optimal time for certain patients with CML to stop TKI treatment.

A phase 3 study showed improved survival rates for patients with high-risk, secondary AML who took Vyxeos.

A recent study showed that for young women who were treated for cancer, the issue of fertility is not adequately addressed.

The FDA expanded the label for Imbruvica for some patients with CLL, as the drug continues to show improved survival benefits.

The FDA granted Blincyto a priority review for certain pediatric patients with ALL.

A recent study showed not only that it is possible to administer chemotherapy in an outpatient setting, but it also can improve patients' quality of life and save money.

The FDA approved Venclexta for patients with CLL who have a 17p deletion and failed at least one prior therapy.